CymaBay Therapeutics (CBAY) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CymaBay Therapeutics has entered into a merger agreement with Gilead Sciences, whereby Gilead will acquire CymaBay through a cash tender offer, followed by a merger. Shareholders of CymaBay will receive $32.50 per share, with the transaction hinging on customary conditions including a majority of CymaBay’s shares being tendered. The deal also offers cash payouts for certain equity awards at the time of the merger’s effective completion. This strategic acquisition is subject to regulatory approvals, and CymaBay is bound by a no-shop clause with stipulations allowing them to consider superior offers under specific conditions.
For further insights into CBAY stock, check out TipRanks’ Stock Analysis page.